$87.4 Million is the total value of Diag Capital Management, LP's 41 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BAX | New | BAXTER INTL INC | $5,656,000 | – | 85,933 | +100.0% | 6.47% | – |
| ATNX | New | ATHENEX INC | $5,445,000 | – | 429,046 | +100.0% | 6.23% | – |
| ZBH | New | ZIMMER BIOMET HLDGS INC | $4,946,000 | – | 47,684 | +100.0% | 5.66% | – |
| ABBV | New | ABBVIE INC | $4,648,000 | – | 50,420 | +100.0% | 5.32% | – |
| INCY | New | INCYTE CORP | $4,591,000 | – | 72,196 | +100.0% | 5.25% | – |
| QTRX | New | QUANTERIX CORP | $4,101,000 | – | 223,949 | +100.0% | 4.69% | – |
| CELG | New | CELGENE CORP | $4,048,000 | – | 63,159 | +100.0% | 4.63% | – |
| AMGN | New | AMGEN INC | $3,915,000 | – | 20,110 | +100.0% | 4.48% | – |
| MDT | New | MEDTRONIC PLC | $3,291,000 | – | 36,180 | +100.0% | 3.76% | – |
| QTNT | New | QUOTIENT LTD | $3,225,000 | – | 526,932 | +100.0% | 3.69% | – |
| New | PACIRA PHARMACEUTICALS INCnote 3.250% 2/0 | $3,205,000 | – | 74,502 | +100.0% | 3.67% | – | |
| TAK | New | TAKEDA PHARMACEUTICAL CO LTDsponsored ads | $2,982,000 | – | 177,260 | +100.0% | 3.41% | – |
| ABT | New | ABBOTT LABS | $2,791,000 | – | 38,585 | +100.0% | 3.19% | – |
| ZLAB | New | ZAI LAB LTDadr | $2,789,000 | – | 120,092 | +100.0% | 3.19% | – |
| MYL | New | MYLAN N V | $2,724,000 | – | 99,410 | +100.0% | 3.12% | – |
| PTE | New | POLARITYTE INC | $2,466,000 | – | 182,833 | +100.0% | 2.82% | – |
| VRAY | New | VIEWRAY INC | $2,412,000 | – | 397,375 | +100.0% | 2.76% | – |
| REGN | New | REGENERON PHARMACEUTICALS | $2,163,000 | – | 5,792 | +100.0% | 2.47% | – |
| TEVA | New | TEVA PHARMACEUTICAL INDS LTDsponsored adr | $2,152,000 | – | 139,531 | +100.0% | 2.46% | – |
| AKRXQ | New | AKORN INC | $2,149,000 | – | 634,046 | +100.0% | 2.46% | – |
| HAE | New | HAEMONETICS CORP | $2,123,000 | – | 21,220 | +100.0% | 2.43% | – |
| ARGX | New | ARGENX SEsponsored adr | $1,606,000 | – | 16,712 | +100.0% | 1.84% | – |
| BHVN | New | BIOHAVEN PHARMACTL HLDG CO L | $1,417,000 | – | 38,319 | +100.0% | 1.62% | – |
| MMSI | New | MERIT MED SYS INC | $1,400,000 | – | 25,092 | +100.0% | 1.60% | – |
| SNY | New | SANOFIsponsored adr | $1,313,000 | – | 30,240 | +100.0% | 1.50% | – |
| GWPH | New | GW PHARMACEUTICALS PLCads | $1,311,000 | – | 13,460 | +100.0% | 1.50% | – |
| LIVN | New | LIVANOVA PLC | $1,095,000 | – | 11,974 | +100.0% | 1.25% | – |
| MTEM | New | MOLECULAR TEMPLATES INC | $985,000 | – | 243,839 | +100.0% | 1.13% | – |
| FOMX | New | FOAMIX PHARMACEUTICALS LTD | $960,000 | – | 146,432 | +100.0% | 1.10% | – |
| VRCA | New | VERRICA PHARMACEUTICALS INC | $937,000 | – | 114,947 | +100.0% | 1.07% | – |
| NBIX | New | NEUROCRINE BIOSCIENCES INC | $876,000 | – | 12,266 | +100.0% | 1.00% | – |
| XRAY | New | DENTSPLY SIRONA INC | $757,000 | – | 20,347 | +100.0% | 0.87% | – |
| AXNX | New | AXONICS MODULATION TECH INC | $702,000 | – | 46,485 | +100.0% | 0.80% | – |
| ARYAU | New | ARYA SCIENCES ACQUISITION COunit 10/04/2023 | $522,000 | – | 50,500 | +100.0% | 0.60% | – |
| ADMA | New | ADMA BIOLOGICS INC | $435,000 | – | 182,100 | +100.0% | 0.50% | – |
| MDGL | New | MADRIGAL PHARMACEUTICALS INC | $326,000 | – | 2,890 | +100.0% | 0.37% | – |
| ARVN | New | ARVINAS INC | $311,000 | – | 24,210 | +100.0% | 0.36% | – |
| New | NOVAVAX INCnote 3.750% 2/0 | $286,000 | – | 155,320 | +100.0% | 0.33% | – | |
| NEOS | New | NEOS THERAPEUTICS INC | $278,000 | – | 168,642 | +100.0% | 0.32% | – |
| ANAB | New | ANAPTYSBIO INC | $95,000 | – | 1,493 | +100.0% | 0.11% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BAXTER INTL INC | 1 | Q4 2018 | 6.5% |
| ATHENEX INC | 1 | Q4 2018 | 6.2% |
| ZIMMER BIOMET HLDGS INC | 1 | Q4 2018 | 5.7% |
| ABBVIE INC | 1 | Q4 2018 | 5.3% |
| INCYTE CORP | 1 | Q4 2018 | 5.3% |
| QUANTERIX CORP | 1 | Q4 2018 | 4.7% |
| CELGENE CORP | 1 | Q4 2018 | 4.6% |
| AMGEN INC | 1 | Q4 2018 | 4.5% |
| MEDTRONIC PLC | 1 | Q4 2018 | 3.8% |
| QUOTIENT LTD | 1 | Q4 2018 | 3.7% |
View Diag Capital Management, LP's complete holdings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.